跳到正文
原文
Endpoints News 生物医药· Ryan Cross·· 1 天前AI 评分42

梅维达伦在轻中度阿尔茨海默病二期临床试验中失败

#CTAD26: Lilly’s dopamine drug mevidalen fails Phase 2 study in Alzheimer’s

AI 导读

梅惠林公司研发的多巴胺药物梅维达伦在治疗轻中度阿尔茨海默病的二期临床试验中失败。

正文

BOSTON — A lit­tle-known ther­a­py Eli Lil­ly has qui­et­ly been test­ing in peo­ple with mild and mod­er­ate Alzheimer’s dis­ease has failed in its Phase 2 study.
…

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news